Dive into a thought-provoking podcast episode exploring the intersection of artificial intelligence and drug discovery. Join host Lukas Biewald as he interviews Isomorphic Labs' Chief AI Officer Max Jaderberg and Chief Technology Officer Sergei Yakneen, both former DeepMind researchers. Discover how AI is revolutionizing the biotech industry, from molecular design to clinical trials. Gain insights into the challenges of applying machine learning to complex biological systems, the potential for AI to streamline drug development, and the ethical considerations surrounding AI in healthcare. Learn about Isomorphic Labs' innovative approach to drug discovery and the transformative impact of deep learning on the pharmaceutical industry. Explore the future of AI-driven healthcare solutions and reflect on the broader implications of artificial intelligence in medicine.
Accelerating Drug Discovery with AI - Insights from Isomorphic Labs
Overview
Syllabus
Episode introduction and guest overview
Max's transition from DeepMind to Isomorphic Labs
Sergei's tech background and move to healthcare
Early challenges at Isomorphic Labs
Integrating AI into drug discovery
Impact of machine learning on drug design
Introducing AI to drug discovery teams
AI's role in predicting drug effects
Future prospects of AI in biotech
AI ethics in healthcare
Broader AI applications in healthcare
Reflections on AI's impact on medicine & wrap-up
Taught by
Weights & Biases
Related Courses
-
Drug Discovery in Prevention and Treatment of COVID-19
-
Accelerating Drug Discovery with Generative AI
-
What's Holding Back AI in Drug Discovery?
-
AI in Drug Discovery: What Do We Need for Being Successful?
-
Harnessing AI for Drug Discovery: From Property Prediction to Molecular Design
-
Chemical Foundation Models for Drug Discovery
